Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV JNJ-64179375 vs oral apixaban after total knee replacement
jRCT2080223833Phase 2
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ichorcumab in venous thromboembolism (VTE) and pulmonary embolism (PE) (2 arms), sponsored by Janssen Pharmaceutical.
02
Drugs
ichorcumab
03
Conditions
venous thromboembolism (VTE)pulmonary embolism (PE)
Beyond the preview
Go deeper on jRCT2080223833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223833.